Skip to main content
menu

Kristen M. O'Dwyer, M.D.

Contact Information

Phone Numbers

Appointment: (585) 275-5823

Office: (585) 275-5823

Fax: (585) 273-1051

URMFGA member of the University of Rochester Medical Faculty Group

groupAn Accountable Health Partner

assignmentAccepting New Patients

Faculty Appointments

Patient Care Settings

Cancer, Hospital Medicine, Hematology & Oncology

Credentials

Education

2003
MD | University of Wisconsin Medical School-Madison

Post-doctoral Training & Residency

07/01/2006 - 06/30/2010
Fellowship in Medical Oncology at Memorial Sloan-Kettering Cancer Center

07/01/2005 - 06/30/2006
Residency in Internal Medicine at New York Presbyterian Hospital/Weill Cornell

06/14/2004 - 06/30/2005
Internship in Internal Medicine at New York Presbyterian Hospital/Weill Cornell

07/01/2003 - 06/30/2004
Internship in Pathology at National Cancer Institute/National Institute of Health

VIEW ALL expand_more

Awards

2016 - Present
Young Investigator Award
Sponsor: Southwest Oncology Group (SWOG)

2010 - 2013
Wilmot Cancer Research Fellowship
Sponsor: University of Rochester School of Medicine and Dentistry
Location: Rochester, NY

2009 - 2010
Young Investigator Award
Sponsor: ASCO Cancer Foundation

2007 - 2009
Clinical Scholars Biomedical Research Fellowship
Sponsor: Memorial Sloan-Kettering Cancer Center

2003 - 2004
National Institutes of Health General Research Loan Repayment Program
Sponsor: NIH

2002 - 2003
Howard Hughes Medical Institute Research Training Fellowship for Medical Students
Sponsor: Hughes

2000 - 2002
NIH Research Scholar, Cloister Program
Sponsor: Hughes

1998
Medical Student Teaching Fellowship. Dept. of Physiology
Sponsor: University of Wisconsin School of Medicine
Location: Madison, WI

VIEW ALL expand_more

Clinical Trials

A Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-Negative CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults or Adults With Relapsed or Refractory Disease,A Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-Negative CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults or Adults With Relapsed or Refractory Disease,A Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-Negative CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults or Adults With Relapsed or Refractory Disease,A Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-Negative CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults or Adults With Relapsed or Refractory Disease

Lead Researcher: Kristen M O'Dwyer

This phase II trial studies how well inotuzumab ozogamicin and blinatumomab work in treating patients with CD22-positive B-lineage acute lymphoblastic leukemia that is newly diagnosed, has come back, or does not respond to treatment. Immunotherapy with monoclonal antibodies, such as inotuzumab ozogamicin and blinatumomab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

View Study Details

A Phase III Randomized Trial of Steroids+Tyrosine Kinase Inhibitor Induction With Chemotherapy or Blinatumomab for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults

Lead Researcher: Kristen M O'Dwyer

This phase III trial compares the effect of usual treatment of chemotherapy and steroids and a tyrosine kinase inhibitor (TKI) to the same treatment plus blinatumomab. Blinatumomab is a Bi-specific T-Cell Engager ('BiTE') that may interfere with the ability of cancer cells to grow and spread. The information gained from this study may help researchers determine if combination therapy with steroids, TKIs, and blinatumomab work better than the standard of care.

View Study Details

A Phase 4, Multi-center Open-label Feasibility Study to Evaluate Outpatient Blinatumomab Administration in Adult Subjects With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (ALL) in Complete Hematologic Remission

Lead Researcher: Kristen M O'Dwyer

The study aims to determine the safety and feasibility of complete outpatient blinatumomab administration for subjects with minimal/measurable residual disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (ALL).

View Study Details

A Phase II Study of AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) in Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL)

Lead Researcher: Kristen M O'Dwyer

This phase II trial studies how well OBI-3424 works in treating patients with T-cell acute lymphoblastic leukemia that has come back (relapsed) or does not response to treatment (refractory). Drugs used in chemotherapy, such as OBI-3424, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. OBI-3424 may reduce the amount of leukemia in the body.

View Study Details

Understanding Causes of Outcome Disparities in Adolescents and Young Adults (AYA) with Acute Lymphoclastic Leukemia (ALL)

Lead Researcher: Kristen M O'Dwyer

We will establish two prospective groups of patients with Acute Lymphoclastic Leukemia (ALL): "Cohort A" will be enrolled on the study at the time of diagnosis while "Cohort B" will be enrolled during maintenance chemotherapy.

View Study Details

Publications

Journal Articles

2022
O'Dwyer KM. "Optimal Approach to T-cell ALL. Hematology Am Soc Hematol Educ Program". 2022; 2022 (1):197-205.

2021
Shah BD; Ghobadi A; Oluwole OO; Logan AC; Boissel N; Cassaday RD; Leguay T; Bishop MR; Topp MS; Tzachanis D; O'Dwyer KM; Arellano ML; Lin Y; Baer MR; Schiller GJ; Park JH; Subklewe M; Abedi M; Minnema MC; Wierda WG; DeAngelo DJ; Stiff P; Jeyakumar D; Feng C; Dong J; Shen T; Milletti F; Rossi JM; Vezan R; Masouleh BK; Houot R. "KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study." 2021; Lancet 2021;398:491-502.

2020
Sekeres MA; Guyatt G; Abel G; Alibhai S; Altman JK; Buckstein R; Choe H; Desai P; Erba H; Hourigan CS; LeBlanc TW; Litzow M; MacEachern J; Michaelis LC; Mukherjee S; O'Dwyer K; Rosko A; Stone R; Agarwal A; Colunga-Lozano LE; Chang Y; Hao Q; Brignardello-Petersen R. "American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults." 2020; .

VIEW ALL PUBLICATIONS

Reviews

At URMC, we believe that patients should be empowered to make the right decisions regarding their personal healthcare. To do so, transparency is critical. URMC partners with Press Ganey, to survey our patients about all aspects of their care experience. We are now putting this pertinent information at your fingertips by displaying star ratings for our providers along with anonymous patient comments on our website. This will help you make better-informed choices about how and with whom you seek care. Click here to learn more about the surveys used to generate this vital information.